Ver­sant part­ners gear up for a $700M bo­nan­za of biotech bets, with a spe­cial fo­cus all their own

3 years ago
Financing

This is the FDA’s year to shine, but can bio­phar­ma keep up as reg­u­la­tors con­tin­ue to rev up chart-top­ping num­bers?

3 years ago
Pharma

A new analy­sis spot­lights the top 20 drugs in the late-stage pipeline

3 years ago
R&D

'Idea Man' Paul Allen leaves be­hind plan to un­scram­ble hu­man im­munol­o­gy

3 years ago
People

Eli Lil­ly is go­ing for it again, ink­ing $2B Alzheimer's deal for tau ther­a­pies with AC Im­mune

3 years ago
Pharma

Clive Mean­well gives way to new CEO as ac­tivist in­vestor Alex Den­ner shakes up The Med­i­cines Com­pa­ny

3 years ago
People

Nas­daq cel­e­brates epic biotech IPO suc­cess in 2018. But can the par­ty on Wall Street rum­ba on?

3 years ago
Financing

Mod­er­na skirts the reefs of dis­as­ter and sails in­to Wall Street with a $604M IPO boun­ty — but shares slide

3 years ago
Financing

Ab­b­Vie’s trou­bled $10B Ro­va-T can­cer drug pro­gram takes a sud­den turn to­ward the cliff

3 years ago
R&D

What do Mar­tin Shkre­li, Gilead and Take­da have in com­mon? They all fig­ure promi­nent­ly in the new top-20 list of the world’s most ex­pen­sive drugs

3 years ago
Special
Pharma

Bis­pecifics vs CAR-T: An­a­lysts se­lect the big win­ners — and losers — at #ASH18's biggest ever dat­a­palooza

3 years ago
R&D

#ASH18: Can Am­gen break through the BC­MA CAR-T line and take a BiTE of the mul­ti­ple myelo­ma mar­ket? It won't be quick or easy

3 years ago
R&D

#ASH18: Al­lo­gene ticks off a high CR rate for up­dat­ed off-the-shelf CAR-T pi­o­neer. But get­ting just the right kind of im­muno­sup­pres­sion is cru­cial

3 years ago
R&D

#ASH18: Leg­end Biotech — al­lied with J&J now — con­tin­ues to wow the crowd with their BC­MA CAR-T up­date. What will blue­bird say?

3 years ago
R&D

#ASH18: BeiGene works to bust through the check­point crowd with a piv­otal read­out that proves its PD-1 is bet­ter than the rest

3 years ago
R&D

#ASH18: Blue­bird and Cel­gene didn’t 'break' their next-gen BC­MA CAR-T, so now they’ll dou­ble down on the dose and root for re­al dura­bil­i­ty

3 years ago
R&D

#ASH18: Gilead posts im­pres­sive sur­vival rates for Yescar­ta — but sales re­main lean

3 years ago
R&D

#ASH18: Cel­gene of­fers up a stel­lar com­plete re­sponse rate for JCAR017. Will any­one no­tice?

3 years ago
R&D

#ASH18: Re­gen­eron's bis­pe­cif­ic REGN1979 of­fers eye-catch­ing 80% CR rate in fol­lic­u­lar lym­phoma, spurring swift shift to piv­otal study

3 years ago
R&D

#ASH18: Ac­celeron and Cel­gene take cen­ter stage with a pair of PhI­I­Is for lus­pa­ter­cept they be­lieve will back up $2B-plus in rev­enue pro­jec­tions

3 years ago
R&D

Amarin just rolled out a bat­tery of promis­ing new da­ta for Vas­cepa — brace your­self for the M&A chat­ter to come

3 years ago
R&D

In­novent, Eli Lil­ly cite a new suc­cess for their PD-1 in lung can­cer, with a like­ly pi­o­neer­ing ap­proval in Chi­na loom­ing

3 years ago
R&D
China

Ex-Ker­ris­dale an­a­lyst sets out to tor­pe­do Nek­tar with a blunt short at­tack on star drug NK­TR-214: 'It doesn’t work'

3 years ago
Pharma

GSK-backed sci­en­tif­ic team at UCSF says they found the im­mor­tal­i­ty switch in can­cer cells — and know how to turn it off

3 years ago
Discovery
First page Previous page 6566676869 Next page Last page